Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14,215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Fukuda M, Oka M, Soda H, Kinoshita A, Fukuda M, Nagashima S, Kuba M, Takatani H, Tsurutani J, Nakamura Y, Kasai T, Inoue Y, Soejima Y, Kohno S; Nagasaki Thoracic Oncology Group. Fukuda M, et al. Among authors: nakamura y. Cancer Chemother Pharmacol. 2004 Dec;54(6):573-7. doi: 10.1007/s00280-004-0805-2. Epub 2004 Sep 10. Cancer Chemother Pharmacol. 2004. PMID: 15365766 Clinical Trial.
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S. Nagashima S, et al. Among authors: nakamura y. Cancer Chemother Pharmacol. 2006 Nov;58(5):594-600. doi: 10.1007/s00280-006-0212-y. Epub 2006 Mar 7. Cancer Chemother Pharmacol. 2006. PMID: 16520985
14,215 results
You have reached the last available page of results. Please see the User Guide for more information.